Economic Impact of Pulmonary Drugs on Direct Costs of Stable Chronic Obstructive Pulmonary Disease

Alonso, José Luís Izquierdo; Miguel-Díez, Javier de

doi:10.1081/copd-120039809

Cited by 49 publications

(34 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[11][12][13][14]34 These costs are not comparable, due to differences in the healthcare systems and methodologies involved. The mean cost in our series is higher than that in studies with similar methodologies and unit prices, 11,12 especially due to baseline treatments (basically inhalers and inhaled Oral antibiotics pooled costs is the sum of costs of all courses of antibiotics that each patient needed for exacerbation during the year. c Exacerbations pooled costs is the sum of costs of all the emergency room visits, hospital admissions and courses of antibiotics that each patient required for exacerbation during the year.…”

Section: Discussionmentioning

confidence: 99%

“…The few studies published to date on the costs associated with BE show that these are high, [8][9][10] and possibly greater than those described for chronic obstructive pulmonary disease (COPD). [11][12][13][14] Since most of the direct costs of the BE management can be attributed to exacerbations and baseline treatment, 15,16 it is reasonable to suppose that more severe patients give rise to higher health costs. This is an important topic, in the light of the current levels of diagnosis, 17,18 hospitalization and mortality 10,19 of BE patients.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Annual direct medical costs of bronchiectasis treatment

et al. 2016

View full text Add to dashboard Cite

Patients with bronchiectasis (BE) present exacerbations that increase with severity of the disease. We aimed to determine the annual cost of BE treatment according to its severity, determined by FACED score, as well as the parameters associated with higher costs. Multicentre historical cohorts study with patients from six hospitals in Spain. The costs arising during the course of a year from maintenance treatment, exacerbations, emergency visits and hospital admissions were analysed. In total, 456 patients were included (56.4% mild BE, 26.8% moderate BE and 16.9% severe BE). The mean cost was €4671.9 per patient, which increased significantly with severity. In mild BE, most of the costs were due to bronchodilators and inhaled steroids; in severe BE, most were due to exacerbations and inhaled antibiotics. Forced expiratory volume in 1 second (FEV 1 %), age, colonization by Pseudomonas aeruginosa and the number of admissions were independently related to higher costs. The highest costs were found in patients with BE associated with chronic obstructive pulmonary disease, with the most exacerbations and with chronic bronchial colonization by Pseudomonas aeruginosa (PA). In conclusion, BE patients gave rise to high annual costs, and these were doubled on each advance in severity on the FACED score. FEV 1 %, age, colonization by PA and the number of admissions were independently related to higher costs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Annual direct medical costs of bronchiectasis treatment

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Aside from the possible comparison with the GOLD guidelines, various studies in recent years have estimated the economic burden of this disease in Spain, showing that the total annual direct cost of COPD per patient varies between €1100 and €3400, with a mean of approximately €2000 [Miravitlles and Figueras, 2001;Miravitlles et al 2003;de Miguel Díez, 2005;Masa et al 2004;Izquierdo-Alonso and de Miguel-Díez, 2004;de Miguel Díez et al 2008]. In our study we found the costs for patients with stage II disease to be in line with previous estimations, but the direct cost observed for patients with stage III disease was around €1900 higher than the average.…”

Section: Discussionmentioning

confidence: 99%

“…Of these, 1.3 (SD 4.7) are to specialists, 0.7 (SD 3.0) to emergency services and patients spend an average of 1 day in hospital (SD 5.3) [Izquierdo-Alonso and de Miguel-Díez, 2004]. From these figures, it was estimated that a sample of 624 patients would allow a difference of 2 days to be detected in the calculation of the mean total number of visits, assuming a maximum SD of 25.5 days and a confidence interval of 95%.…”

Section: Sample Sizementioning

confidence: 99%

Costs of chronic obstructive pulmonary disease in relation to compliance with guidelines: a study in the primary care setting

Miravitlles

Sicras

Crespo

et al. 2013

Ther Adv Respir Dis

View full text Add to dashboard Cite

Background: The aim of this study was to analyse the economic impact of nonadherence to the Global Initiative for Obstructive Lung Disease (GOLD) guidelines in patients with chronic obstructive pulmonary disease (COPD). Methods: A retrospective analysis was carried out on a claim database. Patients aged at least 40 years with a diagnosis of COPD were eligible for this analysis. Demographics, medical data and use of resources were collected and direct and indirect costs were analysed (from January 2008 to June 2009). A probabilistic multivariate sensitivity analysis of avoided costs was carried out. All results are presented in annualized form and costs are expressed in Euros (2009). Results: A total of 1365 patients were included, 79.5% were men. The mean age (±standard deviation) was 71.4 (±10.3) years, the mean forced expiratory volume in 1 s (FEV 1) was 65.3% and they had a COPD history of 5.5 (±2.9) years. Patients were divided into an adherent group and a nonadherent group depending on whether therapeutic recommendations according to severity defined in the GOLD guidelines (2007) were followed. Patients in both groups were also classified as having stage II (FEV 1 < 80% and < 50%) or stage III disease (FEV 1 < 50% and ≥ 30%). The total annual drug cost per patient in the nonadherent group was €771.5 while it was only €426.4 for the adherent group. The average direct cost per patient per year in the nonadherent stage II group was €1465 (±971) and it rose to €2942 (±1918) for patients in the nonadherent group with stage III disease. The potential saving from the implementation of the GOLD guidelines in stage II COPD amounted to €758 per patient per year (68% saving on drug cost). In contrast, the cost for patients with stage III disease was higher in the adherent group versus the nonadherent group (€2468). Conclusions: The cost of COPD may vary according to compliance with the GOLD guidelines. The cost observed for patients with stage II disease is higher than expected in patients who adhere to treatment, but patients with stage III disease treated according to the GOLD guidelines had significantly higher treatment costs.

show abstract

“…17 utilizando como año base 2010, para EPOC se usan los datos de Izquierdo y cols. 18 , utilizando como año base 2004; y para la diabetes se usan los datos de Mata et al 19 …”

Section: Estimación De Los Costes Potencialesunclassified

Ahorro y costes potenciales de una intervención para reducir la no-adherencia de los pacientes crónicos avanzados

Seda

Bernardo

2016

PharmacoEcon Span Res Artic

View full text Add to dashboard Cite

AHORRO Y COSTES POTENCIALES DE UNA INTERVENCIÓN PARA REDUCIR LA NO-ADHERENCIA DE LOS PACIENTES CRÓNICOS AVANZADOS 2 IntroducciónLa adherencia al tratamiento es muy baja entre pacientes crónicos avanzados, implicando un gasto aún más alto del que ya es. Esta situación está empeorando debido al crecimiento exponencial del número de pacientes crónicos. Este estudio estima el beneficio neto de una intervención para la reducción de la no-adherencia, que consiste en monitorizar regularmente a los pacientes para evitar errores en la toma de las medicinas. MétodoSe hace un análisis coste-beneficio. Como coste se calcula el tiempo dedicado a la visita, y como beneficio la reducción del coste sanitario. Se usa la perspectiva social y como año de referencia 2014. También se hace un análisis de sensibilidad, utilizando diferentes valores para la variable eficiencia de la intervención. ResultadosCon una efectividad del 10%, el beneficio neto obtenido aplicando la intervención a una población de 7,5 millones de habitantes sería en 3.804 millones de euros. El beneficio neto, si se aplicara la misma intervención el año 2050, sería de 5.829 millones de euros debido al incremento de la población. Reduciendo la efectividad más de un 80% el beneficio aún sería muy importante. ConclusiónLa aplicación de esta intervención sería muy beneficiosa, no solo por el aumento de la salud de la población diana, sino también por la reducción del gasto sanitario.

show abstract

Economic Impact of Pulmonary Drugs on Direct Costs of Stable Chronic Obstructive Pulmonary Disease

Cited by 49 publications

References 21 publications

Annual direct medical costs of bronchiectasis treatment

Annual direct medical costs of bronchiectasis treatment

Costs of chronic obstructive pulmonary disease in relation to compliance with guidelines: a study in the primary care setting

Ahorro y costes potenciales de una intervención para reducir la no-adherencia de los pacientes crónicos avanzados

Contact Info

Product

Resources

About